Who
Nima Farzan
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics; Chief Executive Officer, Kinnate Biopharma.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $56K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 29 May 2020
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K2,625 at $10.73 | filing |
| 4 Jun 2026filed 8 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K2,625 at $10.73 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,250 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code D | —1,281,642 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code D | —437,413 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code D | —275,000 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code D | —400,000 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code D | —750,000 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharma | SEC FORM 4 Code D | —2,186 | filing |
| 6 Jun 2023filed 8 Jun 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Feb 2023filed 15 Feb 2023 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 10 Feb 2023filed 14 Feb 2023 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,293 at $0.00 | filing |
| 11 Feb 2022filed 15 Feb 2022 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)KROS · tickerreport.com · 24 Oct 2026Comparing Keros Therapeutics (NASDAQ:KROS) and Akebia Therapeutics (NASDAQ:AKBA)KROS · themarketsdaily.com · 24 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Nima Farzan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.